Innovation Is 'Our North Star’ Says Illumina Chief
Next-Generation Sequencing Group Eyeing Growing Role For Genomics In Infectious Disease
Executive Summary
The total addressable market for genomics infectious disease testing is increasing, says Illumina, after becoming the first company to receive a US EUA for a next generation sequencing-based COVID-19 test. It came amid a raft of innovation activity and tuck-in M&A for the San Diego group.